Imunon, Inc. IMNN
Set alert
At close · Oct 30
After hours · Oct 30, 6:38 PM ET
- YTD
- -76.12%
- 1 year
- -79.73%
- Open
- 0.84
- Prev close
- 0.833
- Mkt cap
- 5.11M
- Vol
- 132.52K
- Avg vol
- 107.27K
- EPS
- -3.84
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.84
- High
- 1.00
- Forward P/E
- -0.73
- Beta
- 2.13
- Short ratio
- 3.31
- Inst. own
- 7.03%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.8716
- 200-d avg
- 1.15
- 1y target
- 13.20
News
5 days ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
5 days ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…
-
1 week ago benzinga.com
IMUNON Sells ThermoDox Rights To VoxelDox; IMUNON Receive Equity Ownership Stake In VoxelDox With Payments Of Up To $16.5M Contingent On Meeting Development Milestones And Royalties
Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma TrialSale Reinforces IMUNON's…
1 week ago globenewswire.com
IMUNON Announces Strategic Sale of ThermoDox®
Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial
3 weeks ago globenewswire.com
IMUNON to Participate in Upcoming Investor Conferences
LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $34.9 million. Intelligent Bio Solutions…
1 month ago globenewswire.com
IMUNON Converts $1.2 Million of Debt-to-Equity
Unique investment vehicle provides efficient access to equity capitalOutstanding debt of the original Note lowered by approximately 43% No issuance of common stock or dilutive warrants LAWRENCEVILLE,…
-
1 month ago benzinga.com
IMUNON Reports Overall Survival Results, Advances Phase 3 OVATION 3 Trial
2026 R&D Day presentation highlights include:Review of final Randomized Phase 2 overall survival resultsSupportive Preliminary MRD Study Data and translational findingsPathway to confirmatory readout…
1 month ago globenewswire.com
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory…
1 month ago seekingalpha.com
Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript
Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript
-
1 month ago benzinga.com
IMUNON Says Independent Monitoring Committee Recommends Continuing IMNN-001 Phase 2 Study Without Modification
Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to dateNo cytokine release syndrome, systemic…
1 month ago globenewswire.com
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date
-
1 month ago benzinga.com
IMUNON Enters Into CRADA With National Cancer Institute To Advance DNA-Based IL‑12 Immunotherapy IMNN‑001
Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimensIMUNON retains ownership of its background intellectual property…
1 month ago globenewswire.com
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 48.8% to $3.63 during Thursday's pre-market session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma…
-
1 month ago benzinga.com
IMUNON To Discuss OVATION 1 Clinical Study At Its Sept. 23 R&D Day
IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced the agenda and speaker lineup for its upcoming R&D Day highlighting…
1 month ago globenewswire.com
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J.
2 months ago globenewswire.com
IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001
Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones
2 months ago seekingalpha.com
Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript
Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript
-
2 months ago benzinga.com
Imunon Q2 EPS $(0.54) Beats $(0.93) Estimate
Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.93) by 41.94 percent. This is a 74.88 percent increase over losses of $(2.15) per…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings…
3 months ago globenewswire.com
IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION 2…
3 months ago benzinga.com
EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study
IMUNON posts rapid patient enrollment in its Phase 3 OVATION 3 trial for ovarian cancer, targeting completion by Q2 2029.
-
3 months ago benzinga.com
IMUNON To Present New Data On IMNN-001, DNA-Based Interleukin-12 Immunotherapy For Advanced Ovarian Cancer, At Inaugural AACR Conference On Drug Discovery And Development
Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanismFirst-of-its-kind meeting spotlights…
3 months ago globenewswire.com
IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development
Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism
3 months ago globenewswire.com
IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
Preliminary data reinforces IMNN-001 immunotherapy's potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial Lower rate of minimal residual disease (MRD)Higher ctDNA…
3 months ago benzinga.com
Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients
Imunon Inc. (NASDAQ:IMNN) on Tuesday reported new preliminary findings from its ongoing Phase 2 minimal residual disease (MRD) translational trial.
3 months ago benzinga.com
Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients
Imunon reports early Phase 2 data showing lower residual disease and higher ctDNA clearance with IMNN-001 in ovarian cancer.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.9 million. Imunon (NASDAQ:IMNN) shares…
-
4 months ago benzinga.com
Imunon Says Jeffrey Church To Retire As Interim CFO Effective July 1, 2026; Appoints Josh Blacher As Interim CFO Effective July 1, 2026
On June 29, 2026, Jeffrey Church informed Imunon, Inc. (the "Company") of his intent to retire from the position of interim Chief Financial Officer (a position he has held since January of 2026),…
-
4 months ago benzinga.com
IMUNON Receives Independent Data Monitoring Committee Recommended Continuation Of Pivotal Phase 3 OVATION 3 Clinical Trial Of IMNN-001 In Combination With Standard Of Care Neoadjuvant And Adjuvant Chemotherapy In Women With Newly Diagnosed Advanced Ovarian Cancer
IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the independent Data Monitoring Committee (iDMC) has recommended…
4 months ago globenewswire.com
IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer…
4 months ago globenewswire.com
IMUNON to Present at the Life Sciences Investor Forum on June 25th
LAWRENCEVILLE, N. J. , June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy…
-
5 months ago benzinga.com
IMUNON Enters Into Definitive Agreements For $10M In Preferred Stock And Secured Notes
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 millionUniquely structured, flexible financing supports IMUNON's Highly Anticipated Phase 3…
5 months ago globenewswire.com
IMUNON Announces Up to $10 Million Cash Financing
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports IMUNON's Highly Anticipated Phase 3…
5 months ago seekingalpha.com
Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript
Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
Imunon Reports Q1 2026 Results: Full Earnings Call Transcript
Imunon Reports Q1 2026 Results: Full Earnings Call Transcript
-
5 months ago benzinga.com
Imunon Q1 EPS $(0.84) Beats $(1.07) Estimate
Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.07) by 21.5 percent. This is a 73.33 percent increase over losses of $(3.15) per…
-
6 months ago benzinga.com
Maxim Group Initiates Coverage On Imunon with Buy Rating, Announces Price Target of $10
Maxim Group analyst Jason McCarthy initiates coverage on Imunon (NASDAQ:IMNN) with a Buy rating and announces Price Target of $10.
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
7 months ago benzinga.com
Earnings Scheduled For March 31, 2026
Earnings Scheduled For March 31, 2026
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
11 months ago benzinga.com
Earnings Scheduled For November 13, 2025
Earnings Scheduled For November 13, 2025
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session